Vascular factors, angiogenesis and biliary tract disease

Purpose of review Recent studies have brought to light that angiogenesis and the expression of pro-angiogenic factors such as vascular endothelial growth factors (VEGFs) participate in the pathogenesis of biliary tract diseases. This review summarizes recent progress that has been accomplished in the field, which expands our understanding of the relationship between vascular growth and the biliary tract, particularly the molecular mechanisms that underlie the pathogenesis of biliary tract diseases. Recent findings Angiogenesis and the expression of vascular factors play a key role in the pathogenesis of primary biliary cirrhosis, cholangiocarcinoma, liver cysts, and in the progression of biliary fibrosis in animal models. Inhibition of angiogenesis limits fibrosis in animal models, whereas the bile acid, taurocholate, has protective effects in animal models of bile duct and peribiliary vascular plexus damage. Summary A widening body of information indicates that the expression of pro-angiogenic factors such as VEGFs and angiogenesis play an important role in a variety of biliary tract diseases. Further characterization of the link between angiogenesis and vascular growth factor expression will help in elucidating the mechanisms regulating the pathogenesis of biliary tract diseases and in devising new treatment approaches for these devastating diseases.

[1]  Marie Lin,et al.  Genetic Variation in the Vascular Endothelial Growth Factor Gene is Associated With Biliary Atresia , 2010, Journal of clinical gastroenterology.

[2]  D. Schuppan,et al.  Pharmacological inhibition of integrin αvβ3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis , 2009, Hepatology.

[3]  R. Mancinelli,et al.  H3 Histamine Receptor–Mediated Activation of Protein Kinase Cα Inhibits the Growth of Cholangiocarcinoma In vitro and In vivo , 2009, Molecular Cancer Research.

[4]  Kelley,et al.  Liver Cyst Cytokines Promote Endothelial Cell Proliferation and Development , 2009, Experimental biology and medicine.

[5]  A. Porrello,et al.  Repair‐related activation of hedgehog signaling promotes cholangiocyte chemokine production , 2009, Hepatology.

[6]  B. Bryan,et al.  The function of vascular endothelial growth factor , 2009, BioFactors.

[7]  K. Alitalo,et al.  VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. , 2009, Current opinion in cell biology.

[8]  R. Mancinelli,et al.  Taurocholate Feeding to Bile Duct Ligated Rats Prevents Caffeic Acid-Induced Bile Duct Damage by Changes in Cholangiocyte VEGF Expression , 2009, Experimental biology and medicine.

[9]  M. Mejías,et al.  Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats , 2009, Hepatology.

[10]  S. Hirohashi,et al.  Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma , 2009, British Journal of Cancer.

[11]  R. Mancinelli,et al.  Endothelin inhibits cholangiocarcinoma growth by a decrease in the vascular endothelial growth factor expression , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[12]  A. Franchitto,et al.  Estrogens stimulate the proliferation of human cholangiocarcinoma by inducing the expression and secretion of vascular endothelial growth factor. , 2009, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[13]  K. Iwaisako,et al.  Hepatic stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis. , 2008, Gastroenterology.

[14]  D. Schuppan,et al.  Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression. , 2008, Gastroenterology.

[15]  A. Franchitto,et al.  S1590 Bile Acid Feeding Prevents Hepatic Artery Ligation-Induced Bile Duct Injury in Bile Duct Ligated Rats (BDL) By PI3K/AKT-Dependent Activation of Cholangiocyte VEGF-a Expression , 2008 .

[16]  S. Hirohashi,et al.  Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma , 2007, British Journal of Cancer.

[17]  P. Carmeliet,et al.  Antiangiogenic treatment with Sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats , 2007, Hepatology.

[18]  C. Mack,et al.  The Pathogenesis of Biliary Atresia: Evidence for a Virus-Induced Autoimmune Disease , 2007, Seminars in liver disease.

[19]  A. Franchitto,et al.  H3 histamine receptor agonist inhibits biliary growth of BDL rats by downregulation of the cAMP-dependent PKA/ERK1/2/ELK-1 pathway , 2007, Laboratory Investigation.

[20]  D. Schuppan,et al.  Pharmacological inhibition of the vitronectin receptor abrogates PDGF-BB-induced hepatic stellate cell migration and activation in vitro. , 2007, Journal of hepatology.

[21]  J. Sicklick,et al.  Hedgehog-mediated mesenchymal–epithelial interactions modulate hepatic response to bile duct ligation , 2007, Laboratory Investigation.

[22]  A. Franchitto,et al.  Estrogens and insulin-like growth factor 1 modulate neoplastic cell growth in human cholangiocarcinoma. , 2006, The American journal of pathology.

[23]  A. Franchitto,et al.  Administration of r-VEGF-A prevents hepatic artery ligation-induced bile duct damage in bile duct ligated rats. , 2006, American journal of physiology. Gastrointestinal and liver physiology.

[24]  T. Roskams,et al.  Effects of angiogenic factor overexpression by human and rodent cholangiocytes in polycystic liver diseases , 2006, Hepatology.

[25]  G. Stoica,et al.  Vascular endothelial growth factor stimulates rat cholangiocyte proliferation via an autocrine mechanism. , 2006, Gastroenterology.

[26]  Y. Takeda,et al.  Angiogenesis in cholangiocellular carcinoma: expression of vascular endothelial growth factor, angiopoietin-1/2, thrombospondin-1 and clinicopathological significance. , 2006, Oncology reports.

[27]  S. Friedman,et al.  Reversal of hepatic fibrosis — Fact or fantasy? , 2006, Hepatology.

[28]  C. Spirlí,et al.  Pathophysiology of cholangiopathies. , 2005, Journal of clinical gastroenterology.

[29]  N. LaRusso,et al.  The cholangiopathies: disorders of biliary epithelia. , 2004, Gastroenterology.

[30]  B. Galy,et al.  Hepatocellular hypoxia-induced vascular endothelial growth factor expression and angiogenesis in experimental biliary cirrhosis. , 1999, The American journal of pathology.

[31]  L. Pannarale,et al.  Hepatic microcirculation and peribiliary plexus in experimental biliary cirrhosis: a morphological study. , 1996, Gastroenterology.

[32]  L. Pannarale,et al.  The hepatic microcirculation in experimental cirrhosis. A scanning electron microscopy study of microcorrosion casts. , 1991, Scanning microscopy.

[33]  S. Hirohashi,et al.  Clinicopathological and prognostic significance of EGFR , VEGF , and HER 2 expression in cholangiocarcinoma , 2010 .

[34]  S. Somlo,et al.  ERK1/2-dependent vascular endothelial growth factor signaling sustains cyst growth in polycystin-2 defective mice. , 2010, Gastroenterology.

[35]  R. Witek,et al.  Liver cell-derived microparticles activate hedgehog signaling and alter gene expression in hepatic endothelial cells. , 2009, Gastroenterology.

[36]  S. Glaser,et al.  Proliferating cholangiocytes: a neuroendocrine compartment in the diseased liver. , 2007, Gastroenterology.

[37]  P. Sanz-Cameno,et al.  Evidence of angiogenesis in primary biliary cirrhosis: an immunohistochemical descriptive study. , 2005, Journal of hepatology.